| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 62.64% | 65.46% | 66.91% | 68.61% | 68.69% | 70.25% |
| Operating Margin | 22.41% | 14.85% | 19.76% | 27.41% | 42.22% | 44.82% |
| EBITDA Margin | 26.18% | 18.07% | 22.67% | 30.22% | 45.51% | 48.35% |
| Net Margin | 8.83% | 6.97% | 6.28% | 19.80% | 35.60% | 39.39% |
| Current Ratio | 2.41 | 2.03 | 2.12 | 2.21 | 1.78 | — |
| Quick Ratio | 1.73 | 1.58 | 1.69 | 1.80 | 1.06 | — |
| Debt / Equity | -2.15 | -2.13 | -1.95 | -1.80 | 0.00 | — |
| ROE | -14.66% | -10.61% | -8.57% | -25.08% | 69.80% | — |
| ROA | 8.75% | 6.09% | 5.80% | 20.58% | 52.64% | — |
| Asset Turnover | 0.99 | 0.87 | 0.92 | 1.04 | 1.48 | — |
| Book Value / Share | -11.04 | -12.66 | -14.23 | -15.51 | 10.42 | — |
Embecta Corporation is a dynamic player in the healthcare industry, primarily focused on producing advanced medical devices. Its chief function is to innovate and manufacture devices related to diabetes care, addressing both individual and clinical needs. The corporation plays a crucial role in providing solutions that facilitate the management of diabetes, which is a growing global health concern. Embecta's products are characterized by their reliability and ease of use, significantly impacting the quality of life for patients and assisting healthcare providers in delivering efficient diabetes management. With a strong emphasis on research and development, Embecta Corporation aims to address the ever-evolving medical necessities associated with diabetes. The company operates globally, ensuring broad access to its innovative medical solutions, thereby positioning itself as a vital contributor to the advancement of healthcare technologies and patient care. Through its continued dedication to excellence and innovation, Embecta Corporation holds significant market relevance, serving both individual customers and larger healthcare systems worldwide.